Novavax - Stock

Novavax P/E 2024

Novavax P/E

94.95

Novavax Dividend yield

Ticker

NVAX

ISIN

US6700024010

WKN

A2PKMZ

As of Jun 8, 2024, Novavax's P/E ratio was 94.95, a -6,739.86% change from the -1.43 P/E ratio recorded in the previous year.

The Novavax P/E history

Novavax Aktienanalyse

What does Novavax do?

Novavax Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines and products for the treatment of infectious diseases. The company was founded in 1987 in Maryland, USA, and has since relocated its headquarters to Gaithersburg, Maryland. Novavax is a pioneer in vaccine technology. The company's business model is based on the development of vaccines for diseases such as malaria, Zika, RSV, and COVID-19. Novavax uses the latest technology and methods to ensure the highest efficacy and safety of its vaccines. By licensing its own technologies and licenses, the company has significantly increased its reach and effectiveness, establishing successful partnerships with institutions such as the Bill and Melinda Gates Foundation and the US Department of Defense. The different divisions of the company are focused on the development of vaccines and antiviral therapies. Novavax is involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Currently, Novavax is conducting studies in the field of Respiratory Syncytial Virus (RSV) vaccination. The RSV program is Novavax's oldest program, launched in 1995, and the company has developed several vaccine candidates. A recent Phase III trial of an RSV vaccine candidate for the prevention of RSV infections in pregnant women did not meet its goals. However, it is a key position in vaccine development, allowing the company to focus on the development of vaccines against other infectious diseases. Novavax also has an ongoing research program focused on developing a COVID-19 vaccine candidate based on a protein called Nanoparticle Spike Protein (NVX-CoV2373) expressed in insect cells. A major advantage of this program is that it allows for faster manufacture of millions of doses with high throughput and has consistently shown positive results in clinical studies. The company has also developed a revolutionary technology called Matrix-M, which is used in its vaccines to enhance the immune response and activity against the vaccine. It is an adjuvant technology that stimulates the body to respond to a vaccine and achieve higher immunity against the pathogen. Novavax has a number of vaccine candidates in clinical development, including vaccines against malaria, influenza, and human papillomavirus (HPV), as well as an antiviral therapy for the treatment of RSV. These programs are still in the early stages of development, but the company is confident that it will be successful in the future. Overall, Novavax is a company specializing in the development of innovative vaccines and antiviral therapies for the treatment of infectious diseases. With a focus on safety, efficacy, and innovation, the company has achieved a leading position in vaccine technology and has become a key player in the global health landscape. Answer: Novavax is a biopharmaceutical company that specializes in developing and marketing innovative vaccines and products for treating infectious diseases. It was founded in 1987 in Maryland, USA, and focuses on developing vaccines against diseases like malaria, Zika, RSV, and COVID-19. The company uses advanced technology and methods to ensure the effectiveness and safety of its vaccines. It has partnerships with institutions like the Bill and Melinda Gates Foundation and the US Department of Defense. Novavax is also involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Its oldest program is focused on developing an RSV vaccine, and it also has a program focused on developing a COVID-19 vaccine. Novavax has developed a technology called Matrix-M, which enhances the immune response to vaccines. It also has vaccine candidates in development for malaria, influenza, and HPV, as well as an antiviral therapy for RSV. Overall, Novavax is a leading company in vaccine technology and aims to develop effective and innovative vaccines and antiviral therapies for infectious diseases. Novavax ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Novavax's P/E Ratio

The Price to Earnings (P/E) Ratio of Novavax is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Novavax's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Novavax is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Novavax’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Novavax Stock

What is the price-to-earnings ratio of Novavax?

The price-earnings ratio of Novavax is currently 94.95.

How has the price-earnings ratio of Novavax changed compared to last year?

The price-to-earnings ratio of Novavax has increased by -6,739.86% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Novavax high compared to other companies?

Yes, the price-to-earnings ratio of Novavax is high compared to other companies.

How does an increase in the price-earnings ratio of Novavax affect the company?

An increase in the price-earnings ratio of Novavax would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Novavax affect the company?

A decrease in the price-earnings ratio of Novavax would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Novavax?

Some factors that influence the price-earnings ratio of Novavax are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Novavax pay?

Over the past 12 months, Novavax paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novavax is expected to pay a dividend of 0 USD.

What is the dividend yield of Novavax?

The current dividend yield of Novavax is .

When does Novavax pay dividends?

Novavax pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Novavax?

Novavax paid dividends every year for the past 0 years.

What is the dividend of Novavax?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Novavax located?

Novavax is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novavax kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novavax from 6/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/8/2024.

When did Novavax pay the last dividend?

The last dividend was paid out on 6/8/2024.

What was the dividend of Novavax in the year 2023?

In the year 2023, Novavax distributed 0 USD as dividends.

In which currency does Novavax pay out the dividend?

The dividends of Novavax are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novavax stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital

Andere Kennzahlen von Novavax

Our stock analysis for Novavax Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novavax Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.